2024
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients
Brahmer J, Long G, Hamid O, Garon E, Herbst R, Andre T, Armand P, Bajorin D, Bellmunt J, Burtness B, Choueiri T, Cohen E, Diaz L, Shitara K, Kulkarni G, McDermott D, Shah M, Tabernero J, Vogel A, Zinzani P, Jafari N, Bird S, Snyder E, Gause C, Bracco O, Pietanza M, Gruber T, Ribas A. Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients. European Journal Of Cancer 2024, 199: 113530. PMID: 38295556, PMCID: PMC11227881, DOI: 10.1016/j.ejca.2024.113530.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsMelanomaConceptsImmune-mediated adverse eventsAdverse eventsInfusion reactionsSafety profileClinical trialsPembrolizumab discontinuationPembrolizumab monotherapyNon-small cell lung cancerSafety of pembrolizumabDose of pembrolizumabTreated with prednisoneCell lung cancerLow steroid dosesPopulation of patientsSteroid doseMedian durationPembrolizumabAE onsetPooled analysisLung cancerCancer clinical trialsSafety dataPatientsCancer typesInfusion
2023
First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer—What Happened?
Burtness B. First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer—What Happened? Journal Of Clinical Oncology 2023, 41: 2134-2137. PMID: 36877893, DOI: 10.1200/jco.22.02349.Peer-Reviewed Original Research
2013
Modern Chemotherapy Mitigates Adverse Prognostic Effect of Regional Nodal Metastases in Stage IV Colorectal Cancer
Thomay AA, Nagorney DM, Cohen SJ, Sigurdson ER, Truty MJ, Burtness B, Hall MJ, Chun YS. Modern Chemotherapy Mitigates Adverse Prognostic Effect of Regional Nodal Metastases in Stage IV Colorectal Cancer. Journal Of Gastrointestinal Surgery 2013, 18: 69-74. PMID: 24002765, DOI: 10.1007/s11605-013-2329-8.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCamptothecinColorectal NeoplasmsFemaleHepatectomyHumansIrinotecanKaplan-Meier EstimateLiver NeoplasmsLung NeoplasmsLymph NodesLymphatic MetastasisMaleMiddle AgedNeoplasm StagingOrganoplatinum CompoundsOvarian NeoplasmsOxaliplatinPeritoneal NeoplasmsPrognosisRetrospective StudiesYoung AdultConceptsStage IV colorectal cancerLymph node ratioPositive regional nodesRegional lymph nodesRegional nodal metastasesColorectal cancerPositive nodesOverall survivalRegional nodesLiver metastasesLymph nodesNodal metastasisPrognostic significanceModern chemotherapyMetastatic regional lymph nodesStage IV diseasePrimary tumor resectionTertiary referral centerDate of diagnosisAdverse prognostic effectMedian OSPerioperative oxaliplatinReferral centerPrognostic factorsRetrospective review
2011
A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck
Argiris A, Ghebremichael M, Burtness B, Axelrod RS, Deconti RC, Forastiere AA. A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck. Cancer 2011, 117: 3374-3382. PMID: 21246525, PMCID: PMC3135694, DOI: 10.1002/cncr.25852.Peer-Reviewed Original ResearchConceptsAdenoid cystic carcinomaStable diseaseEvaluable patientsObjective responseCystic carcinomaEastern Cooperative Oncology Group performance status 0Day 1Common distant metastatic siteGrade 3 sensory neuropathyMedian progression-free survivalMetastatic adenoid cystic carcinomaGrade 3 anorexiaPerformance status 0Phase 2 trialProgression-free survivalTime of progressionSingle-agent bortezomibCombination of bortezomibDistant metastatic sitesAddition of doxorubicinMeasurable diseaseStatus 0Disease stabilizationFrequent toxicitiesPrior therapy
2010
Molecular selection for 'smart' study design in lung cancer
Psyrri A, Burtness B. Molecular selection for 'smart' study design in lung cancer. Nature Reviews Clinical Oncology 2010, 7: 621-622. PMID: 20981127, DOI: 10.1038/nrclinonc.2010.156.Peer-Reviewed Original ResearchDetection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients
Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA, Gilbert J, Murphy B, Caprioli RM, Carbone DP, Cohen EE. Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients. Cancer Epidemiology Biomarkers & Prevention 2010, 19: 358-365. PMID: 20086114, PMCID: PMC2846615, DOI: 10.1158/1055-9965.epi-09-0937.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBevacizumabBiomarkers, TumorCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCetuximabColorectal NeoplasmsErbB ReceptorsErlotinib HydrochlorideGefitinibHead and Neck NeoplasmsHumansKaplan-Meier EstimateLung NeoplasmsMass SpectrometryMutationProtein Kinase InhibitorsProteomicsProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)QuinazolinesRas ProteinsSignal TransductionSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationConceptsCRC patientsColorectal cancerCancer patientsNon-small cell lung cancer patientsEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsNon-small cell lung cancerRecurrent/metastatic headCell lung cancer patientsNeck squamous cell carcinomaLigand levelsReceptor tyrosine kinase inhibitorsCell lung cancerSquamous cell carcinomaLung cancer patientsKRAS mutation statusTyrosine kinase inhibitorsProteomic classificationSerum proteomic profilesDiverse cancer typesSite of originChemotherapy cohortMetastatic headPretreatment serumSurvival benefit
2005
Remarkably High Frequency of EGFR Expression in Breast Carcinomas with Squamous Differentiation
Bossuyt V, Fadare O, Martel M, Ocal IT, Burtness B, Moinfar F, Leibl S, Tavassoli FA. Remarkably High Frequency of EGFR Expression in Breast Carcinomas with Squamous Differentiation. International Journal Of Surgical Pathology 2005, 13: 319-327. PMID: 16273187, DOI: 10.1177/106689690501300403.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBone NeoplasmsBreast NeoplasmsCarcinoma, AdenosquamousCarcinoma, Squamous CellCarcinosarcomaCell DifferentiationErbB ReceptorsFollow-Up StudiesHumansImmunohistochemistryKeratinsLung NeoplasmsLymph NodesLymphatic MetastasisMiddle AgedNeoplasm StagingReceptor, ErbB-2Receptors, EstrogenConceptsEpidermal growth factor receptorDisease-free survivalSquamous differentiationBreast carcinomaEstrogen receptorLymph nodesHER2 statusTissue microarrayEGFR expressionFull axillary lymph node dissectionAxillary lymph node dissectionLymph node positive breast carcinomaNode-positive breast carcinomaHuman epidermal growth factor receptorEGFR-negative tumorsLymph node dissectionPositive lymph nodesLymph node statusPositive breast carcinomaEGFR-positive tumorsEGFR-positive tumor cellsGrowth factor receptorNode dissectionEGFR positivityDistant metastasis
2001
Use of paclitaxel in patients with pre‐existing cardiomyopathy: A review of our experience
Gollerkeri A, Harrold L, Rose M, Jain D, Burtness B. Use of paclitaxel in patients with pre‐existing cardiomyopathy: A review of our experience. International Journal Of Cancer 2001, 93: 139-141. PMID: 11391633, DOI: 10.1002/ijc.1295.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionYale Cancer CenterPaclitaxel therapyClinic recordsDecreased LVEFCompletion of paclitaxelPre-existing cardiomyopathyPrior cardiac diseasePrior doxorubicin therapySecond-line agentsCongestive heart failureVentricular ejection fractionUse of paclitaxelEffect of paclitaxelEjection fractionHeart failureCardiac dysfunctionClinical evidenceOutpatient clinicCancer CenterCardiac toxicityDoxorubicin therapyCardiac functionRetrospective analysisMean change
2000
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.
Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D’Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. Journal Of Clinical Oncology 2000, 18: 904-14. PMID: 10673534, DOI: 10.1200/jco.2000.18.4.904.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsArea Under CurveCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCetuximabCisplatinDose-Response Relationship, DrugDrug Administration ScheduleErbB ReceptorsFemaleGene Expression Regulation, NeoplasticHead and Neck NeoplasmsHumansInfusions, IntravenousLung NeoplasmsMaleNeoplasms, Glandular and EpithelialRecombinant Fusion ProteinsRemission InductionSafetyConceptsAntibody dosesMultiple doseSystemic clearancePhase I clinical trialWeeks of therapyDose-dependent pharmacokineticsCell lung cancerChimeric monoclonal antibodyCoadministration of cisplatinEpidermal growth factor receptorMurine chimeric monoclonal antibodyGrowth factor receptorDisease stabilizationPartial responseAdvanced tumorsSingle doseLung cancerClinical trialsDisease progressionEpithelial tumorsNonlinear pharmacokineticsPatientsDose levelsAntibody C225Relevant doses
1997
Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer.
Murren JR, Anderson S, Fedele J, Pizzorno G, Belliveau D, Zelterman D, Burtness BA, Tocino I, Flynn SD, Beidler D, Cheng YC. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. Journal Of Clinical Oncology 1997, 15: 148-57. PMID: 8996136, DOI: 10.1200/jco.1997.15.1.148.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsMaximum-tolerated doseMg/ m2/dDose of topotecanM2/dRefractory cancerDay 1Treatment cyclesDrug-induced DNA fragmentationGrowth factor supportTransfusion of RBCsDose of cyclophosphamideFirst treatment cycleAdministration of cyclophosphamideGranulocyte colony-stimulating factorPharmacokinetics of topotecanClass of agentsColony-stimulating factorBlood cell elementsBolus scheduleNonhematologic toxicityReversible neutropeniaDNA fragmentationFactor supportCombination therapy